Related Experiment Video
Updated: Jun 6, 2026
Analysis of HBV-Specific CD4 T-cell Responses and Identification of HLA-DR-Restricted CD4 T-Cell Epitopes Based on a Peptide Matrix
Published on: October 20, 2021
HLA-B*5701 testing to predict abacavir hypersensitivity
Joseph D Ma1, Kelly C Lee, Grace M Kuo
1University of California, San Diego, Skaggs School of Pharmacy & Pharmaceutical Sciences and University of California, San Diego, Skaggs School of Pharmacy and Pharmaceutical Sciences.
Abstract:
Abacavir is a nucleoside reverse transcriptase inhibitor used for combination antiretroviral therapy for treating human immunodeficiency virus (HIV) infection. An adverse effect from abacavir is a treatment-limiting hypersensitivity reaction, which can be severe and potentially life-threatening. Abacavir-induced hypersensitivity reaction has been associated with the presence of the major histocompatibility complex class I allele HLA-B*5701. A screening test for the HLA-B*5701 allele can assist clinicians to identify patients who are at risk of developing a hypersensitivity reaction to abacavir.
